Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
《生物技術日報》:CormediX、Mersana和葛蘭素史克在《癌症協議》中遭遇監管挫折,BARDA有望爲阿片類藥物過量提供資金
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Mersana Therapeutics Inc (NASDAQ:MRSN) announced a global collaboration that provides GSK plc (NYSE:GSK) an exclusive option to co-develop and commercialize XMT-2056.
Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.
Mersana has retained options to profit-share and to co...
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要:
Stocks In Focus
焦點股票
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Mersana、葛蘭素史克簽署了13.6億美元的抗癌療法Biobuck協議
Mersana Therapeutics Inc (NASDAQ:MRSN) announced a global collaboration that provides GSK plc (NYSE:GSK) an exclusive option to co-develop and commercialize XMT-2056.
Mersana Thareutics納斯達克股票代碼:MRSN)宣佈了一項全球合作,該合作提供葛蘭素史克公司(紐約證券交易所代碼:GSK)是共同開發和商業化 XMT-2056 的獨家選擇。
Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.
Mersana將獲得1億美元的預付期權購買費。如果葛蘭素史克行使期權,Mersana還有資格獲得高達13.6億美元的期權行使補助和開發、監管和商業里程碑補助金。
Mersana has retained options to profit-share and to co...
Mersana保留了...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!